… efficacy of gefitinib in patients with uncommon mutations, we conducted a post-hoc analysis
of the NEJ002, which compared gefitinib … advanced NSCLC with activating EGFR mutations. …

… -TKIs in NSCLC patients with common and rare EGFR mutations. To the best of our … the
efficacy of erlotinib, gefitinib, and afatinib in patients with rare and common EGFR mutations. …

… efficacy of gefitinib in brain metastases from NSCLC and evaluated the association of this
efficacy with EGFR mutations… association between the efficacy of gefitinib and EGFR mutations. …

… Therefore, this study has a bias against the effectiveness of gefitinib. Further prospective
or retrospective multicenter studies with large sample sizes are warranted. However, this …

… gefitinib in patients with NSCLC according to the type of active EGFR mutation, ie exon 19
deletion or L858R point mutation… point mutation of EGFR who were on gefitinib treatment. The …

… -small cell lung cancer (NSCLC) to gefitinib, an EGFR tyrosine kinase inhibitor. The clinical
… the efficacy of gefitinib in patients with stageIII/IV NSCLC that had the EGFR mutations. …

… the efficacy of gefitinib and erlotinib in patients with pulmonary adenocarcinoma, whose
tumor EGFR mutation … Pulmonary adenocarcinoma patients who began receiving gefitinib or …

… EGFR mutation screening, it also examined the influence of EGFR mutations on the efficacy
of … can be the most important predictive factor for efficacy of TK inhibitors, so we analyzed …

… Our study confirms the previous efficacy data of afatinib for NSCLC harboring uncommon
EGFR mutations other than T790M. Compared with gefitinib and erlotinib, afatinib treatment …

… gefitinib had a similar efficacy in advanced squamous cell lung cancer. The frequency of
EGFR mutation … The efficacy was similar between erlotinib and gefitinib regardless of the PFS …